18 May 2018 | News | By NFS Correspondent
OptiBiotix Health has signed a five-year exclusive manufacturing and supply agreement for its cholesterol and blood pressure reducing strain in India.
OptiBiotix, which develops a range of compounds to tackle obesity, high cholesterol, diabetes and skin care, has stated that the agreement has been carried out with Akums Drugs and Pharmaceuticals Ltd, a leading contract manufacturer in India.
Under the terms of the agreement, Akums will manufacture and supply products containing OptiBiotix’s LPLDL strain throughout India to maximise financial return for both parties.
Akums will also contribute to any required human studies for product marketing purposes or by the Food Safety Standards Authority of India (FSSAI) as part of product registration into food.
Akums is the largest contract manufacturing organisation in India, supplying more than 12% of all food and drug supplements consumed in the country, and has manufacturing partnerships with over 600 companies including Abbott, Novartis, P&G, Sanofi and Sandoz, in the pharmaceutical and food supplement space.